May 25, 2012 3:15 PM | 1 min read
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Amylin (NASDAQ: AMLN) shares are surging in late afternoon trade on Friday after Bloomberg reported that the biotech firm has received first-round bids from Sanofi SA (NYSE: SNY) and Merck (NYSE: MRK). According to sources, these bids were for at least $25.00 per share. The company has put itself up for sale and is being advised by Credit Suisse (NYSE: CS) and Goldman Sachs (NYSE: GS) during the process. The offers would value AMLN at over $4 billion. Currently, the stock has jumped around 8% to $27.85, giving the company a valuation in excess of $4.5 billion. In addition, Takeda Pharmaceutical and Bristol-Myers Squibb (NYSE: BMY) have indicated that they will be submitting buyout bids for Amylin. Furthermore, Pfizer (NYSE: PFE), AstraZeneca (NYSE: AZN) and Roche Holding have signed confidentiality agreements regarding Amylin's sale process, but it is not clear if these companies also plan on submitting bids. The sale of the company comes in the wake of a January FDA decision to approve Amylin's diabetes drug Bydureon, a once-weekly formulation of its earlier drug Byetta. Subsequently, Bristol-Myers Squibb unsuccessfully tried to buy the company for $22.00 per share.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.